New drug combo aims to fight tough childhood cancers
NCT ID NCT06521567
First seen Nov 12, 2025 · Last updated Apr 30, 2026 · Updated 17 times
Summary
This study tests a combination of two drugs, cobolimab and dostarlimab, in children and young adults (up to age 21) with advanced solid tumors like melanoma, brain tumors, and bone cancer. The goal is to find the safest dose and see if the treatment can shrink tumors. Participants must have tried other treatments first. The study is active but not recruiting new participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Los Angeles, California, 90048, United States
-
GSK Investigational Site
Iowa City, Iowa, 52242, United States
-
GSK Investigational Site
Hackensack, New Jersey, 07601, United States
-
GSK Investigational Site
Cincinnati, Ohio, 45229, United States
-
GSK Investigational Site
Providence, Rhode Island, 02903, United States
-
GSK Investigational Site
Madison, Wisconsin, 53792, United States
-
GSK Investigational Site
Brno, 61300, Czechia
-
GSK Investigational Site
Phaha 5, 15006, Czechia
-
GSK Investigational Site
Copenhagen, 2100, Denmark
-
GSK Investigational Site
Bordeaux, 33076, France
-
GSK Investigational Site
Lyon, 69373, France
-
GSK Investigational Site
Paris, 75248, France
-
GSK Investigational Site
Strasbourg, 67098, France
-
GSK Investigational Site
Villejuif, 94805, France
-
GSK Investigational Site
Bologna, 40138, Italy
-
GSK Investigational Site
Naples, 80123, Italy
-
GSK Investigational Site
Barcelona, 08035, Spain
-
GSK Investigational Site
Madrid, 28009, Spain
-
GSK Investigational Site
Madrid, 28046, Spain
-
GSK Investigational Site
Valencia, 46026, Spain
Conditions
Explore the condition pages connected to this study.